Edition:
United Kingdom

Fortress Biotech Inc (FBIO.OQ)

FBIO.OQ on NASDAQ Stock Exchange Capital Market

3.12USD
20 Jun 2018
Change (% chg)

$0.04 (+1.30%)
Prev Close
$3.08
Open
$3.08
Day's High
$3.12
Day's Low
$3.03
Volume
26,370
Avg. Vol
38,779
52-wk High
$5.53
52-wk Low
$2.79

Latest Key Developments (Source: Significant Developments)

Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain
Monday, 21 May 2018 

May 21 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL.AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS.AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019.  Full Article

Mustang Bio Reports Q4 Financial Results
Thursday, 29 Mar 2018 

March 29 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.FORTRESS BIOTECH - ‍AS OF DEC 31, 2017, MUSTANG'S CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND RESTRICTED CASH TOTALED $61.5 MILLION.  Full Article

Avenue Says Dosed First Patient in Phase 3 Safety Trial of IV Tramadol
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Avenue Therapeutics Inc ::AVENUE THERAPEUTICS ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 3 SAFETY TRIAL OF INTRAVENOUS TRAMADOL FOR THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - COMPANY EXPECTS TO INITIATE A SECOND PHASE 3 TRIAL IN PATIENTS FOLLOWING ABDOMINOPLASTY SURGERY IN Q3 OF 2018.AVENUE THERAPEUTICS- EVALUATING IV TRAMADOL IN PHASE 3 TRIAL IN PATIENTS FOLLOWING BUNIONECTOMY SURGERY, EXPECTS TO REPORT TOPLINE DATA IN Q2,2018.  Full Article

Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Fortress Biotech Inc ::MUSTANG BIO'S MB-102 (CD123 CAR) CAR T THERAPY ACHIEVES COMPLETE RESPONSE IN ACUTE MYELOID LEUKEMIA AND BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PHASE 1 CLINICAL TRIAL.MUSTANG BIO - INVESTIGATORS FOUND INFUSIONS OF MB-102 ARE SAFE AND WELL TOLERATED.MUSTANG BIO - CAR T THERAPY IS SAFE, WELL TOLERATED.  Full Article

Mustang Bio reports Q3 loss per share of $0.27
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Mustang Bio::Mustang Bio reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.27.  Full Article

Fortress Biotech posts Q3 loss per share $0.67
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Fortress Biotech Inc :Fortress Biotech reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.67.Q3 revenue $46.9 million versus $1.0 million.  Full Article

Fortress Biotech announces pricing of series a preferred stock offering
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Fortress Biotech Inc :Fortress Biotech Inc announces pricing of series a preferred stock offering.Fortress Biotech Inc - ‍priced offering of one million shares of its 9.375 pct series a cumulative redeemable perpetual preferred stock at $25.00 per share​.  Full Article

Fortress Biotech proposes public offering of Series A preferred stock
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Fortress Biotech Inc :Fortress Biotech announces proposed public offering of Series A preferred stock.  Full Article

Mustang Bio enters lease agreement for production of Car T therapies
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Fortress Biotech Inc :Entered lease agreement for manufacturing facility to support clinical development, commercialization of co's Car T product candidates​.Facility is expected to be operational for production of personalized Car T therapies in 2018​.Has entered into a lease agreement with UMASS Medicine Science Park in Worcester, Massachusetts​.  Full Article

Mustang Bio announces $12.8 mln grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Fortress Biotech Inc ::Mustang Bio announces $12.8 million grant to fund Phase 1 trial of CAR T therapy MB-101 in malignant glioma.  Full Article

BRIEF-Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain

* AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN